NASDAQ
9.34USD
+0.02 (+0.21%)
We have scored 19 news catalysts on Immunic, Inc. (IMUX) over the past 12 months. The biggest single-day move next to one of them came Nov 15, 2025, when IMUX closed +9.3%: “Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI”. Coverage across the window leans positive (average ticker sentiment +0.48). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
127.2M
P/E
—
EPS
—
Beta
1.41
52W range
5.06-17.43
Day range
9.11–9.42
Open
9.42
Prev close
9.32
Volume
250.8K
Avg volume
235.5K
Dividend
0.00
IPO
2014-04-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Immunic, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IMUX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
